

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/106879 A1

(51) International Patent Classification:

A61K 31/13 (2006.01) A61K 31/015 (2006.01)

A61K 31/12 (2006.01) A61K 31/025 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/056215

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

15 November 2024 (15.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/599,280 15 November 2023 (15.11.2023) US

63/567,605 20 March 2024 (20.03.2024) US

63/646,041 13 May 2024 (13.05.2024) US

(71) Applicant: **GILGAMESH PHARMACEUTICALS, INC.** [US/US]; 113 University Place - Suite 1019, New York, New York 10003 (US).

(72) Inventors: **KRUEGEL, Andrew Carry**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place - Suite 1019, New York, New York 10003 (US). **MAREK, George Joseph**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place - Suite 1019, New York, New York 10003 (US). **HUGHES, Zoe A.**; c/o Gilgamesh Pharmaceuticals, Inc., 113 University Place - Suite 1019, New York, New York 10003 (US).

(74) Agent: **GROLZ, Edward**; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, New York 11530 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: METHODS OF TREATING PSYCHIATRIC DISORDERS OR PAIN USING (R)-2-(4-FLUOROPHENYL)-2-(METHYLAMINO)CYCLOHEXAN-1-ONE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

(57) Abstract: The present disclosure relates to methods of treating a patient having a psychiatric disorder or pain comprising administering to the patient in need thereof a base compound or a pharmaceutically acceptable salt thereof as defined herein in specific dosing regimens.

WO 2025/106879 A1